Please assess the completion status of the following clinical trial:

Trial Title: Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion criteria:~* HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by western blot prior to study entry~  * HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test~* Anal human papilloma virus DNA PCR-negative for either type 16 and/or type 18 within 90 days prior to entry~* If receiving antiretroviral therapy:~  * Receipt of antiretroviral therapy for at least 6 months prior to entry~ * No change in antiretroviral therapy within 30 days prior to entry~ * CD4 cell count \> 200 cells/mm³ within 90 days prior to study entry~ * HIV-1 RNA \< 200 copies/mL within 90 days prior to entry~* If not receiving antiretroviral therapy:~  * CD4 cell count ≥ 350 cells/mm³ within 90 days prior to study entry~ * No plans to start antiretroviral therapy prior to week 28~* Normal anal cytological result, or atypical squamous cell of undetermined significance or low-grade squamous intraepithelial lesions (SIL) result within 90 days prior to entry~Exclusion criteria:~* Current or history of anal or perianal carcinoma~* Anal cytological result of high-grade SIL (HSIL), atypical squamous cells suggestive of HSIL, or suggestive of invasive carcinoma at screening or a history of these results~* Presence of high-grade anal intraepithelial neoplasm (HGAIN) (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3), or invasive carcinoma at pre-entry, or history of HGAIN~  * Current or history of anal or peri-anal condyloma is allowed~PATIENT CHARACTERISTICS:~Inclusion criteria:~* Karnofsky performance status 70-100%~* Absolute neutrophil count \> 750 cells/mm³~* Hemoglobin ≥ 9.0 g/dL~* Platelet count ≥ 100,000/mm³~* Creatinine clearance ≥ 60 mL/min~* AST and ALT ≤ 3 times ULN~* Total or conjugated (direct) bilirubin ≤ 2.5 times ULN~Exclusion criteria:~* Serious medical or psychiatric illness, active drug or alcohol use, or dependence that, in the opinion of the site Investigator, would interfere with adherence to study requirements~* Serious illness requiring systemic treatment and/or hospitalization within the past 45 days~* Allergy to yeast or any of the components of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine~* Hemophilia~PRIOR CONCURRENT THERAPY:~Inclusion criteria:~* See Disease Characteristics~Exclusion criteria:~* Prior splenectomy~* Currently receiving anticoagulation therapy other than acetylsalicylic acid~* Use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids, investigational vaccines, interleukins, interferons, growth factors, or IVIG within 45 days prior to study entry~  * Routine standard of care, including hepatitis A or B, influenza, or pneumococcal and tetanus vaccines are not excluded~ * Hepatitis C co-infected patients are eligible provided no concurrent initiation of treatment for hepatitis C~* Prior receipt of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine or other HPV vaccine

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gardasil (Type: EXPERIMENTAL): Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete